Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non–small cell lung cancer
ABSTRACT ROS1 fusion-positive non–small cell lung cancer (NSCLC), occurring in 1–2% of patients, represents a rare but clinically important subset. Patients with ROS1 fusion-positive NSCLC are often younger and tend to have little or no history of smoking. Current first-generation tyrosine kinase inhibitors (TKIs) such...